Patient-derived cellular assays are developed from either primary or stem cells (human embryonic or induced pluripotent) and from either healthy or diseased donors, all to demonstrate the correct biological context.

Over the years, Charles River has established a network of collaborators to access patient-derived cells across numerous therapeutic areas. Combining these patient-derived cells with our CRISPR/Cas9 platform allows generation of the most relevant cell systems; those with mutations, reporters, or isogenic controls.


We offer customized patient-derived cellular assay development such as qPCR, digital droplet PCR, Next-gen Sequencing, and screening including high-content imaging screening with multiparameter detection (HT-FACS, Luminex, and Meso Scale Discovery).


  • Patient derived from tissue, blood, and differentiated stem cells
  • Patient derived from healthy donors or donors with defined disease characteristics
  • CRISPR/Cas9 editing capabilities
  • Over 100 cellular assays
  • High-content imaging screening platforms
  • Protein (Luminex, MesoScale) and RNA (qPCR, digital droplet PCR, and NGS) readouts
  • Scientific expertise in patient-derived cells for more than 20 disease indications
  • Mechanism of action studies using adenoviral SilenceSelect® and FLeXSelect® libraries


RNA Fluorescence In Situ Hybridization by High-Content Imaging

RNA Fluorescence In Situ Hybridization by High-Content Imaging

Human primary fibroblasts from Scleroderma patients. mRNA expression of α-smooth muscle actin, a fibrosis marker, and a housekeeping gene (EEF1A1) were determined using fluorescence in situ hybridization (FISH). Images were obtained by high content imaging (IN Cell 2200, GE Healthcare). Nuclei were stained with DAPI.